Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 824 across all filing types
Latest filing 2023-03-15 Regulatory Filings
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
The company's financial results for 2022 reported abroad
Regulatory Filings
2023-03-15 Hebrew (modern)
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed by a Foreign Private Issuer (Kamada Ltd.) for the month of March 2023 with the SEC. The core content of the filing, detailed in Exhibit 99.1, is an announcement stating that the company "will release financial results for the fourth quarter and full year ended December 31, 2022, prior to the open of the U.S. financial markets on Wednesday, March 15, 2023" and will host a conference call. This is a classic announcement of upcoming financial results, not the results themselves (which would likely be an ER or IR filing). Since the document's primary purpose is to announce the timing of the release of financial results and a conference call, it fits best under the category for announcing report publication or a general regulatory filing. Given the specific nature of announcing the release of financial results, it is closely related to an Earnings Release (ER) or a Report Publication Announcement (RPA). However, the Form 6-K itself is a general regulatory filing mechanism for foreign private issuers. Since the content is purely an announcement about *when* the ER/CT will happen, and it doesn't contain the actual financial highlights (ER) or the transcript (CT), the most appropriate classification among the provided options is either RPA (Report Publication Announcement) or RNS (Regulatory Filings - fallback). Because the document is a formal SEC filing (Form 6-K) announcing the date of the ER/CT, and RPA is defined as announcing the timing/release of reports, RPA is a strong fit. However, Form 6-K is a broad category. Given the options, and the fact that it's an SEC filing announcing future events, RNS (Regulatory Filings) is a safe fallback, but RPA specifically covers announcing the publication of reports. Since the document is a formal SEC filing (Form 6-K) that *contains* the announcement (Exhibit 99.1), and it is not the actual Earnings Release (ER) or Call Transcript (CT), classifying it as RPA (Report Publication Announcement) is the most precise fit based on the exhibit content, which announces the release of financial results and the subsequent call.
2023-03-09 English
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
Report Publication Announcement Classification · 1% confidence The document is extremely short (1950 characters) and its primary purpose is to announce that financial results (Fourth Quarter and Full Year 2022) will be released on a future date (March 15, 2023) and that a conference call will be hosted. It explicitly states, "Attached hereto is a report on..." and references a PDF file. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report is attached or published, without containing the full report details, should be classified as a Report Publication Announcement (RPA). This is an announcement about the upcoming release of earnings/annual results, not the results themselves (ER or 10-K).
2023-03-09 English
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'FORM 6-K' and is filed 'For the Month of January 2023' by a 'Report of Foreign Private Issuer'. Form 6-K is a periodic report required by the SEC for foreign private issuers, which generally corresponds to interim or current reports not covered by the standard US forms (like 10-K or 10-Q). The content is an announcement regarding the submission of an application to the U.S. FDA concerning manufacturing CYTOGAM®. This type of material, which is a current report filed on a specific SEC form (6-K) that doesn't fit the definitions of 10-K, AR, ER, or IR, is best classified under the general regulatory filing category, which is RNS (Regulatory Filings) in this schema, as 6-K filings are often used for material events not covered by other specific US forms. Since the provided definitions do not explicitly list '6-K', RNS serves as the most appropriate fallback for a general, material regulatory filing announcement.
2023-01-04 English
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel
Regulatory Filings Classification · 1% confidence The document is very short (1953 characters) and explicitly states, "Attached hereto is a report on*Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM£ at the Company’s Facility in Israel* *ea171189-6k_kamadaEDGAR1_Bannerless_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report or filing, rather than the full report content. It is filed as an 'Immediate Report' under Israeli regulations (Regulation 4) and broadcast via MAGNA to the Tel Aviv Stock Exchange (TASE). Since it is an announcement of a filing/report and does not fit specific categories like DIV, DIRS, or ER, the most appropriate classification based on Rule 2 (Menu vs Meal) and the general nature of regulatory announcements is Report Publication Announcement (RPA) or Regulatory Filing (RNS). Given the context of announcing a specific regulatory event (FDA submission) and attaching a PDF, RPA is slightly more precise than the general RNS fallback, although RNS would also be plausible. I will select RPA as it announces the publication of information.
2023-01-04 English
Notice of Results of the 2022 Annual General Meeting of Shareholders held on December 22, 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934." The content details the results of an Annual General Meeting (AGM) held on December 22, 2022, including the election of directors and approval of various proposals. Since the document reports the *results* of the shareholder vote from the AGM, it aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA). Although it concerns an AGM, the primary function here is reporting the outcome of the votes, not providing the presentation materials (AGM-R) or the proxy solicitation (PSI). Given the specific nature of reporting voting outcomes, DVA is the most precise fit.
2022-12-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.